Compare ALSN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALSN | ROIV |
|---|---|---|
| Founded | 1915 | 2014 |
| Country | United States | United Kingdom |
| Employees | 4000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1B | 20.7B |
| IPO Year | 2011 | 2021 |
| Metric | ALSN | ROIV |
|---|---|---|
| Price | $113.60 | $28.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $113.75 | $27.56 |
| AVG Volume (30 Days) | 841.3K | ★ 4.7M |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 7.33 | N/A |
| Revenue | ★ $3,010,000,000.00 | $29,053,000.00 |
| Revenue This Year | $58.64 | N/A |
| Revenue Next Year | $3.48 | $385.85 |
| P/E Ratio | $15.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $76.01 | $8.73 |
| 52 Week High | $128.85 | $30.33 |
| Indicator | ALSN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 43.09 | 54.64 |
| Support Level | $108.50 | $26.94 |
| Resistance Level | $128.85 | N/A |
| Average True Range (ATR) | 3.75 | 1.01 |
| MACD | -1.65 | -0.26 |
| Stochastic Oscillator | 15.41 | 38.46 |
Allison Transmission is the largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles. Its automatic transmissions allow customers to achieve better fuel and operator efficiency than less expensive manual and automated manual transmissions. Allison serves several end markets, including on- and off-highway equipment and military vehicles. Its on-highway business commands approximately 60% global market share. The company's transmissions can be found in Class 4-8 trucks, buses, and a limited number of large passenger vehicles (heavy-duty pickup trucks and motorhomes). Allison also produces commercial hybrid propulsion systems and is developing fully electric powertrains.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.